A Study of AT-02 in Subjects With Systemic Amyloidosis.
Status:
Recruiting
Trial end date:
2026-02-28
Target enrollment:
Participant gender:
Summary
This is a Phase 2 open-label extension study to evaluate the long-term safety, tolerability,
and clinical activity of AT-02.
AT-02 is an investigational medicinal product being developed to treat systemic amyloidosis.